CompoAtlas

Phytostandard d'Aubépine et de Passiflore

Food supplement declared in France, declaration No 2017-5-421

Phytostandard d'Aubépine et de Passiflore, from PILEJE, is a food supplement declared in France. Status: earlier declaration, replaced by the 2017 declaration. Main ingredients: Passiflora incarnata 160 mg per day, Crataegus monogyna 20 mg per day, Crataegus laevigata 20 mg per day, Fibres solubles d'acacia. None of the rules we check flags an issue with its declared composition.

Brand
not provided
Food business operator placing the product on the market
PILEJE
Status
Earlier declaration, replaced by the 2017 declaration : Phytostandard d'Aubépine et de Passiflore
Form
Tablet
Daily dose
1 comprimé
Directions for use
1 comprimé par jour, à avaler avec un grand verre d'eau.

Declaration 268825, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Passiflora incarnata L.Parties aériennesExtrait sec hydroalcoolique160 mg
Crataegus monogyna Jacq.Sommités fleuriesExtrait sec hydroalcoolique20 mg
Crataegus laevigata (Poir.) DC.Sommités fleuriesExtrait sec hydroalcoolique20 mg

Other active ingredients

NamePer day
Fibres solubles d'acacianot declared

Additives

E460, E470b, E551, E468

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Une consommation excessive peut avoir des effets laxatifs.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Passiflora incarnata L.
    Read the warning, when it applies and the studies cited

    PASSIONFLOWER -PASSIFLORA INCARNATA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).

    Sources cited by Health Canada (2)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach, 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2014).

    Sources cited by Health Canada (1)
    • EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf

    Health Canada monograph dated 29 November 2024

  • Crataegus monogyna Jacq.
    Read the warning, when it applies and the studies cited

    Hawthorn

    Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Health Canada monograph dated 31 July 2026

  • Crataegus laevigata (Poir.) DC.
    Read the warning, when it applies and the studies cited

    Hawthorn

    Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Health Canada monograph dated 31 July 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line